The groundbreaking treatment of this peptide represents a significant development in the handling of the condition. Different to existing therapies, tirzepatide affects two pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – leading to enhanced glucose control and anticipated weight reduction. Researchers are studying its